Protagonist Therapeutics

PTGX · NASDAQ

$137.99+$3.55 (+2.64%)TodayMarket closed · Oct 20, 5:03 PM ET

Prev close $134.44

Latest news

Press releaseOct 20, 8:59 AM ETPRNewswire
A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday
Press releaseSep 8, 4:05 PM ETACCESS Newswire
Protagonist Therapeutics Announces $300 Million Share Repurchase Program
Press releaseSep 2, 7:05 AM ETACCESS Newswire
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026
NewsAug 31, 12:38 PM ETVandana Singh
Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug
Press releaseAug 28, 8:30 PM ETACCESS Newswire
Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera
NewsAug 13, 1:07 PM ETVandana Singh
Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder Drug
NewsAug 5, 6:07 PM ET
Protagonist Therapeutics Q2 EPS $2.29 Beats $1.66 Estimate, Sales $213.475M Beat $203.764M Estimate
Press releaseAug 5, 4:05 PM ETACCESS Newswire
Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update
NewsJun 24, 2:22 PM ETVandana Singh
This $300 Million Biotech May Be Deeply Mispriced: Analyst
NewsJun 22, 9:15 AM ETVandana Singh
AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition
NewsJun 12, 10:47 AM ETVandana Singh
Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data
NewsMay 5, 4:39 PM ET
Protagonist Therapeutics Q1 EPS $0.05 Beats $(0.42) Estimate, Sales $56.368M Beat $16.273M Estimate
Press releaseMay 5, 4:05 PM ETACCESS Newswire
Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update
Press releaseApr 28, 9:05 AM ETACCESS Newswire
Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration
Press releaseMar 28, 10:05 AM ETACCESS Newswire
Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting
Press releaseMar 2, 2:00 AM ETBusiness Wire
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
NewsFeb 26, 4:00 PM ET
A Glimpse Into The Expert Outlook On Protagonist Therapeutics Through 8 Analysts
NewsFeb 25, 4:50 PM ET
Protagonist Therapeutics Q4 Earnings Summary & Key Takeaways
NewsFeb 25, 4:50 PM ET
Protagonist Therapeutics Q4 EPS $(0.69) Misses $(0.24) Estimate, Sales $7.437M Miss $8.926M Estimate
NewsJan 30, 2:00 PM ET
Breaking Down Protagonist Therapeutics: 8 Analysts Share Their Views
Press releaseJan 5, 7:00 AM ETBusiness Wire
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
Press releaseDec 6, 9:30 AM ETBusiness Wire
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
Press releaseNov 6, 4:05 PM ETACCESS Newswire
Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update
NewsOct 14, 8:51 AM ETVandana Singh
Johnson & Johnson To Separate Orthopedics Business, Boosts Annual Sales Outlook
NewsOct 13, 12:27 PM ETChris Katje
Johnson & Johnson Q3 Preview: With Stock Near All-Time Highs, Here's What To Watch
NewsOct 13, 10:30 AM ETVandana Singh
FDA Adds New Warning For Johnson & Johnson's Cancer Cell Therapy
Press releaseJul 21, 8:05 AM ETACCESS Newswire
Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis
Press releaseJun 1, 8:00 AM ETBusiness Wire
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera
NewsMar 16, 10:40 AM ETLekha Gupta
D-Wave Quantum And IonQ Are Among Top Mid-Cap Stock Gainers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio?
Press releaseMar 10, 8:15 AM ETACCESS Newswire
Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis
Press releaseMar 8, 9:15 AM ETACCESS Newswire
Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis
Press releaseMar 3, 6:45 AM ETBusiness Wire
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
Press releaseDec 17, 2:00 PM ETBusiness Wire
Clear Street Launches Healthcare & Biotechnology Equity Research
NewsNov 13, 12:35 PM ET
10 Health Care Stocks With Whale Alerts In Today's Session
NewsJul 28, 2:17 PM ETLekha Gupta
ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio?
NewsJul 24, 10:46 AM ETAvi Kapoor
AT&T, Group 1 Automotive, Mattel, Seagate And Other Big Stocks Moving Higher On Wednesday

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday

Protagonist Therapeutics Announces $300 Million Share Repurchase Program

Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026

Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug

Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera

Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder Drug

Protagonist Therapeutics Q2 EPS $2.29 Beats $1.66 Estimate, Sales $213.475M Beat $203.764M Estimate

Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update

This $300 Million Biotech May Be Deeply Mispriced: Analyst

AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition

Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data

Protagonist Therapeutics Q1 EPS $0.05 Beats $(0.42) Estimate, Sales $56.368M Beat $16.273M Estimate

Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update

Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration

Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting

Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera

A Glimpse Into The Expert Outlook On Protagonist Therapeutics Through 8 Analysts

Protagonist Therapeutics Q4 Earnings Summary & Key Takeaways

Protagonist Therapeutics Q4 EPS $(0.69) Misses $(0.24) Estimate, Sales $7.437M Miss $8.926M Estimate

Breaking Down Protagonist Therapeutics: 8 Analysts Share Their Views

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Johnson & Johnson To Separate Orthopedics Business, Boosts Annual Sales Outlook

Johnson & Johnson Q3 Preview: With Stock Near All-Time Highs, Here's What To Watch

FDA Adds New Warning For Johnson & Johnson's Cancer Cell Therapy

Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

D-Wave Quantum And IonQ Are Among Top Mid-Cap Stock Gainers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio?

Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis

Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

Clear Street Launches Healthcare & Biotechnology Equity Research

10 Health Care Stocks With Whale Alerts In Today's Session

ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio?

AT&T, Group 1 Automotive, Mattel, Seagate And Other Big Stocks Moving Higher On Wednesday